1-(1-methylvinyl)pyrrolidin-2-one | 45657-19-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 1-(1-methylvinyl)pyrrolidin-2-one
• 英文别名: 1-(prop-1-en-2-yl)pyrrolidin-2-one；1-Prop-1-en-2-ylpyrrolidin-2-one
• CAS: 45657-19-0
• 化学式: C₇H₁₁NO
• 分子量: 125.17
• InChiKey: HMPUKFGKTNAIRX-UHFFFAOYSA-N

物化性质

• 沸点：
  236.5±7.0 °C(Predicted)
• 密度：
  1.027±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  6-乙酰氧基-2H-吡喃-3(6H)-酮 、 1-(1-methylvinyl)pyrrolidin-2-one 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 36.0h， 以25%的产率得到
  参考文献：
  名称：

  Diastereoselective 1,3-dipolar cycloaddition of pyrylium ylides with chiral enamides

  摘要：

  发现手性烯酰胺5f–i与吡啶阳离子反应，生成了立体选择性极高的环加成物6d–i，并且产率良好。在连续流动（H-Cube）条件下对化合物6f进行氢解，成功去除了手性辅助基，首次实现复杂胺8的非对称合成。

  DOI：

  10.1039/c2ob07007c
• 作为产物：
  描述：

  2-吡咯烷酮 、 2-溴丙烯 在 copper(l) iodide 、 potassium carbonate 、 N,N'-二甲基乙二胺 作用下， 以 甲苯 为溶剂， 反应 38.0h， 以55%的产率得到1-(1-methylvinyl)pyrrolidin-2-one
  参考文献：
  名称：

  Free-Radical Carbo-alkenylation of Enamides and Ene-carbamates

  摘要：

  The addition of xanthates and vinyldisulfones across the double bond of enamides and ene-carbamates provides access to the corresponding three.. component adducts in good to excellent yields with a high level of diastereocontrol in cyclic systems. This strategy illustrates a complementary reactivity for these versatile olefins and extends their scope of application.

  DOI：

  10.1021/ol401147w

文献信息

• [EN] PYRIMIDINE DERIVATIVES CAPABLE OF INHIBITING ONE OR MORE KINASES<br/>[FR] DÉRIVÉS DE PYRIMIDINE CAPABLES D'INHIBER UNE OU PLUSIEURS KINASES
  申请人：MEDICAL RES COUNCIL

  公开号：WO2009122180A1

  公开（公告）日：2009-10-08

  A first aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, formula (I): wherein: R1 is C3-8-cycloalkyl; X is O, NR7 or C3-6-heterocycloalkyl; R2 is aryl, heteroaryl, fused or unfused aryl-C3-6-heterocycloalkyl or fused or unfused heteroaryl-C3-6-heterocycIoalkyl, each of which is optionally substituted by one or more substitutents selected from aryl, heteroaryl, C1-6-alkyl, C3-7-cycloalkyl and a group A, wherein said C1-6-alkyl group is optionally substituted by one or more substituents selected from aryl, heteroaryl, R10 and a group A, said heteroaryl group is optionally substituted by one or more R10 groups; and wherein said C3-6-heterocycloalkyl group optionally contains one or more groups selected from oxygen, sulfur, nitrogen and CO; R3 is C1-6-alkyl optionally substituted by one or more substituents selected from aryl, heteroaryl, -NR4R5, -OR6, -NR7(CO)R6, -NR7(CO)NR4R5, -NR7SO2R6, -NR7COOR7, -CONR4R5, C3-6-heterocycloalkyl and formula (a, b, c): wherein R4-7 and A are as defined in the claims. Further aspects relate to the use of said compounds in the treatment of various therapeutic disorders, and more particularly as inhibitors of one or more kinases.

  本发明的第一个方面涉及式(I)的化合物，或其药学上可接受的盐或酯，式(I)如下：其中：R1为C3-8环烷基；X为O、NR7或C3-6杂环烷基；R2为芳基、杂芳基、融合或未融合的芳基-C3-6杂环烷基或融合或未融合的杂芳基-C3-6杂环烷基，每个基可选择地由来自芳基、杂芳基、C1-6烷基、C3-7环烷基和A基的一个或多个取代基取代，其中所述C1-6烷基基可选择地由来自芳基、杂芳基、R10和A基的一个或多个取代基取代，所述杂芳基可选择地由一个或多个R10基取代；以及所述C3-6杂环烷基基可选择地包含一个或多个来自氧、硫、氮和CO的基；R3为C1-6烷基，可选择地由一个或多个来自芳基、杂芳基、-NR4R5、-OR6、-NR7(CO)R6、-NR7(CO)NR4R5、-NR7SO2R6、-NR7COOR7、-CONR4R5、C3-6杂环烷基和式(a, b, c)的取代基取代；其中R4-7和A如权利要求中所定义。进一步方面涉及所述化合物在治疗各种治疗性疾病中的使用，特别是作为一个或多个激酶的抑制剂。
• [EN] HEMI-AMINAL ETHERS AND THIOETHERS OF N-ALKENYL CYCLIC COMPOUNDS<br/>[FR] ÉTHERS ET THIOÉTHERS HÉMIAMINAUX DE COMPOSÉS CYCLIQUES N-ALCÉNYLIQUES
  申请人：ISP INVESTMENTS INC

  公开号：WO2014116560A1

  公开（公告）日：2014-07-31

  Described herein are hemi-aminal ethers and thioethers of N-alkenyl cyclic compounds that may be produced through a reaction comprising: (A) at least one first reactant represented by a structure (I), wherein X is a functionalized or unfunctionalized C1-C5 alkylene group optionally having one or more heteroatoms, and each R1, R2, and R3 is independently selected from the group consisting of hydrogen and functionalized and unfunctionalized alkyl groups optionally having one or more heteroatoms, and (B) at least one second reactant having at least one hydroxyl moiety or thiol moiety. The hemi-aminal ethers and thioethers of N-alkenyl cyclic compounds may comprise a polymerizable moiety, in which case they may be left as-is or used to create homopolymers or non-homopolymers, or they may not comprise a polymerizable moiety. A wide variety of formulations may be created using the hemi-aminal ethers and thioethers of N-alkenyl cyclic compounds, including personal care, oilfield, and construction formulations.

  本文描述了可以通过反应制备的N-烯基环状化合物的半胺醚和硫醚，所述反应包括：（A）至少一个由结构（I）表示的第一反应物，其中X是一个官能化或非官能化的C1-C5烷基烯烃基团，可选地具有一个或多个杂原子，每个R1、R2和R3分别独立地选自氢和官能化和非官能化的烷基基团，可选地具有一个或多个杂原子；和（B）至少一个具有至少一个羟基基团或硫醇基团的第二反应物。N-烯基环状化合物的半胺醚和硫醚可能包括一个可聚合的基团，此时它们可以保持原样或用于制备同聚物或非同聚物，或者它们可能不包括可聚合的基团。可以使用N-烯基环状化合物的半胺醚和硫醚制备各种配方，包括个人护理、油田和建筑配方。
• Visible-light-promoted and photocatalyst-free trifluoromethylation of enamides
  作者：Hao Wang、Yuanzheng Cheng、Shouyun Yu

  DOI：10.1007/s11426-015-5528-1

  日期：2016.2

  An efficient and practical method is developed for the trifluoromethylation of enamides using Umemoto’s reagent as the trifluoromethylating reagent. These reactions proceeded under visible light irradiation without any photocatalyst at room temperature in good chemical yields.

  开发了一种有效且实用的方法，用于使用梅本试剂作为三氟甲基化试剂进行酰胺的三氟甲基化。这些反应在室温下在无任何光催化剂的情况下在可见光照射下进行，化学收率良好。
• Rearrangement of isoxazoline-5-spiro derivatives. Part 7. Thermal rearrangement of 4,5-dihydro and tetrahydroisoxazole-5-spirocyclobutanes to azepin-4-one derivatives
  作者：Andrea Goti、Alberto Brandi、Francesco De Sarlo、Antonio Guarna

  DOI：10.1016/s0040-4020(01)89026-8

  日期：——

  respectively. When subjected to flash vacuum thermolysis conditions, the spiranic cycloadducts rearranged to afford mainly the desired azepin-4-one derivatives. In addition, the isoxazoline cycloadducts gave unexpected by-products, which were identified as 1-alkenyl-2-pyrrolidinones. Analogies and differences with respect to the lower homologue cyclopropanes are evidenced in both cycloaddition and rearrangement

  一些代表性的4，5-二氢和四氢异恶唑5-螺环丁烷是通过亚烷基环丁烷的1，3-偶极环加成分别合成腈氧化物和硝酮而合成的。当经受闪蒸真空热解条件时，芳基环加合物重新排列以主要提供所需的氮杂庚-4-酮衍生物。另外，异恶唑啉环加合物产生意外的副产物，其被鉴定为1-烯基-2-吡咯烷酮。在环加成反应和重排反应中均证明了与低级同系环丙烷的相似性和差异。
• Percutaneous absorption-type pharmaceutical preparation
  申请人：Inosaka Keigo

  公开号：US20060275354A1

  公开（公告）日：2006-12-07

  A stable percutaneous absorption-type pharmaceutical preparation for percutaneous administration of drugs except for selegiline and selegiline hydrochloride, which does not suffer a decrease in the cohesive force of the adhesive layer therein even in the presence of sweat components due to perspiration during wear and which is free from cohesive failure and resultant adhesive remaining when stripped off. A percutaneous absorption-type pharmaceutical preparation which comprises: a support; and an adhesive layer containing an adhesive, a metal chloride and a percutaneously-absorptive drug except for selegiline and selegiline hydrochloride, wherein the adhesive layer is subjected to a crosslinking treatment.

  一种稳定的经皮吸收型药物制剂，用于除去赛洛吉林和赛洛吉林盐酸盐以外的药物的经皮给药，即使在穿戴过程中由于出汗而存在汗液成分时也不会减少粘合层的粘合力，并且在剥离时不会出现内聚力失效和残留粘合剂。一种经皮吸收型药物制剂，包括：一种支撑物；和一个含有粘合剂、金属氯化物和除赛洛吉林和赛洛吉林盐酸盐之外的经皮吸收药物的粘合层，其中粘合层经过交联处理。